Investigation on Mechanisms of Glycopeptide Nanoparticles for Drug Delivery Across The Blood–Brain Barrier
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
AIM: Nanoneuroscience, based on the use polymeric nanoparticles (NPs), represents an emerging field of research for achieving an effective therapy for neurodegenerative diseases. In particular, poly-lactide-co-glycolide (PLGA) glyco-heptapetide-conjugated NPs (g7-NPs) were shown to be able to cross the blood-brain barrier (BBB). However, the in vivo mechanisms of the BBB crossing of this kind of NP has not been investigated until now. This article aimed to develop a deep understanding of the mechanism of BBB crossing of the modified NPs. MATERIALS & METHODS: Loperamide and rhodamine-123 (model drugs unable to cross the BBB) were loaded into NPs, composed of a mixture of PLGA, differently modified with g7 or with a random sequence of the same aminoamids (random-g7). To study brain targeting of these model drugs, loaded NPs were administered via the tail vein in rats in order to perform both pharmacological studies and biodistribution analysis along with fluorescent, confocal and electron microscopy analysis, in order to achieve the NP BBB crossing mechanism. Computational analysis on the conformation of the g7- and random-g7-NPs of the NP surface was also developed. RESULTS: Only loperamide delivered to the brain with g7-NPs created a high central analgesia, corresponding to the 14% of the injected dose, and data were confirmed by biodistribution studies. Electron photomicrographs showed the ability of g7-NPs in crossing the BBB as evidenced by several endocytotic vesicles and macropinocytotic processes. The computational analysis on g7 and random-g7 showed a different conformation (linear vs globular), thus suggesting a different interaction with the BBB. CONCLUSION: Taken together, this evidence suggested that g7-NP BBB crossing is enabled by multiple pathways, mainly membrane-membrane interaction and macropinocytosis-like mechanisms. The results of the computational analysis showed the Biousian structure of the g7 peptide, in contrast to random-g7 peptide (globular conformation), suggesting that this difference is pivotal in explaining the BBB crossing and allowing us to hypothesize regarding the mechanism of BBB crossing by g7-NPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443
Zensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438
Cited by
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Georgieva, J., Hoekstra, D., & Zuhorn, I. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6040557 · Cited by 211
“The macropinocytosis-like mechanism, which appears to depend on the Biousian structure of the peptide, is likely the mechanism by which these nanoparticles translocate across the BBB [111].”
BackgroundValenza, M., Chen, J. Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., Leoni, V., Caccia, C., Brilli, E., Di Donato, S., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505413 · Cited by 112
Self-citationTosi, G., Vilella, A., Chhabra, R., Schmeisser, M. J., Boeckers, T. M., Ruozi, B., Vandelli, M. A., Forni, F., Zoli, M., & Grabrucker, A. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.01.004 · Cited by 56
Self-citationNanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems
Grabrucker, A. M., Chhabra, R., Belletti, D., Forni, F., Vandelli, M. A., Ruozi, B., & Tosi, G. (2013) · Topics in Medicinal Chemistry · doi:10.1007/7355_2013_22 · Cited by 53
Self-citationA Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
Tomaselli, S., La Vitola, P., Pagano, K., Brandi, E., Santamaria, G., Galante, D., D’Arrigo, C., Moni, L., Lambruschini, C., Banfi, L., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00241 · Cited by 29
Pramoda, G., Verma, R. K., Kesharwani, P., & Shukla, R. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127938 · Cited by 15
Metadata
- Authors
- Tosi, G., Fano, R. A., Bondioli, L., Badiali, L., Benassi, R., Rivasi, F., Ruozi, B., Forni, F., & Vandelli, M. A.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2011-04
- Volume
- 6
- Issue
- 3
- Pages
- 423-436
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2167360442
- Cited by
- 99
- References
- 4
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.